Advanced search
Start date
Betweenand
Related content
(Reference retrieved automatically from Web of Science through information on FAPESP grant and its corresponding number as mentioned in the publication by the authors.)

Immunotherapy of tuberculosis with Mycobacterium leprae Hsp65 as a DNA vaccine triggers cross-reactive antibodies against mammalian Hsp60 but not pathological autoimmunity

Full text
Author(s):
Show less -
Doimo, Nayara T. S. [1] ; Zarate-Blades, Carlos R. [1] ; Rodrigues, Rodrigo F. [1] ; Tefe-Silva, Cristiane [2] ; Trotte, Marcele N. S. [3] ; Souza, Patricia R. M. [1] ; Soares, Luana S. [1] ; Rios, Wendy M. [1] ; Floriano, Elaine M. [2] ; Brandao, Izaira T. [1] ; Masson, Ana P. [1] ; Coelho, Veronica [4, 5] ; Ramos, Simone G. [2] ; Silva, Celio L. [1]
Total Authors: 14
Affiliation:
[1] Univ Sao Paulo, Ribeirao Preto Sch Med, Dept Biochem & Immunol, Ctr TB Res, Sao Paulo - Brazil
[2] Univ Sao Paulo, Ribeirao Preto Sch Med, Dept Pathol, Sao Paulo - Brazil
[3] Univ Estado Rio De Janeiro, Vet Med Dept Anat Pathol, Rio De Janeiro - Brazil
[4] Univ Sao Paulo, Sch Med, Heart Inst InCor, Immunol Lab, Sao Paulo - Brazil
[5] NIST, Inst Invest Immunol 3, Sao Paulo - Brazil
Total Affiliations: 5
Document type: Journal article
Source: HUMAN VACCINES & IMMUNOTHERAPEUTICS; v. 10, n. 5, p. 1238-1243, MAY 2014.
Web of Science Citations: 2
Abstract

Despite substantial efforts in recent years toward the development of new vaccines and drugs against tuberculosis (TB), success has remained elusive. Immunotherapy of TB with mycobacterial Hsp65 as a DNA vaccine (DNA-hsp65) results in a reduction of systemic bacterial loads and lung tissue damage, but the high homology of Hsp65 with the mammalian protein raises concern that pathological autoimmune responses may also be triggered. We searched for autoimmune responses elicited by DNA-hsp65 immunotherapy in mice chronically infected with TB by evaluating the humoral immune response and comprehensive histopathology using stereology. Cross-reactive antibodies between mycobacterial and mammalian Hsp60/65 were detected; however, no signs of pathological autoimmunity were found up to 60 days after the end of the therapy. (AU)

FAPESP's process: 09/06793-7 - Autoimmune response evaluation during the immunotherapy of tuberculosis with DNAhsp65
Grantee:Nayara Trevisan dos Santos Doimo
Support Opportunities: Scholarships in Brazil - Scientific Initiation